Bausch & Lomb Corp (BLCO) Guidance & Earnings Results

On 2026-07-29 Bausch & Lomb Corp raised guidance: "FY26 revenue raised to $5.44-5.54B from $5.42-5.52B; constant currency growth 5.8-7.7% (from 5.3-7.2%); FY26 Adjusted EBITDA Excluding Acquired IPR&D…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

BLCOBausch & Lomb CorpFollow BLCO — free

Medical Instruments & Supplies · Healthcare

—

Price chart with a free account

Market cap: 6.2B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 28 Oct, in 4 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
29 Jul 26	Raised	FY26 revenue raised to $5.44-5.54B from $5.42-5.52B; constant currency growth 5.8-7.7% (from 5.3-7.2%); FY26 Adjusted EBITDA Excluding Acquired IPR&D raised · full year
29 Apr 26	Raised	FY2026 revenue raised to $5.420B-$5.520B from $5.375B-$5.475B; FY2026 Adjusted EBITDA ex-IPR&D raised to $1.010B-$1.060B from $1.000B-$1.050B; FY2026 revenue FX tailwinds increased to $50M from $30M · full year
18 Feb 26	Raised	FY2026 revenue $5.375B - $5.475B (5-7% constant currency growth); FY2026 Adj. EBITDA Excl. Acquired IPR&D $1.000B - $1.050B; FY2026 revenue FX tailwinds $30M · full year
29 Oct 25	Raised	Full-year 2025 revenue $5.050B-$5.150B (unchanged); Full-year Adjusted EBITDA Excluding Acquired IPR&D $870M-$910M (raised from $860M-$910M); Full-year Revenue FX tailwinds $30M (from $25M) · full year
30 Jul 25	Raised	FY2025 revenue raised to $5.05-5.15B from $5.00-5.10B · full year

Bausch & Lomb Corp — questions

What guidance did Bausch & Lomb Corp give?: On 2026-07-29: "FY26 revenue raised to $5.44-5.54B from $5.42-5.52B; constant currency growth 5.8-7.7% (from 5.3-7.2%); FY26 Adjusted EBITDA Excluding Acquired IPR&D raised"
When does Bausch & Lomb Corp report earnings?: Bausch & Lomb Corp's next earnings report is expected on 2026-10-28.

Every figure on this page comes from Bausch & Lomb Corp's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.